iCAD’s Xoft Intraoperative Radiation Therapy System Featured at American Society of Breast Surgeons Conference
Booth #303--iCAD,
Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and
radiation therapy technologies for the detection and treatment of
cancer, today announced that the Company’s Xoft® Axxent®
Electronic Brachytherapy System® for Intraoperative Radiation
Therapy (IORT) will be a featured subject of several scientific and
training sessions at the American Society of Breast Surgeons’ 14th
Annual Meeting taking place this week at the Sheraton Chicago Hotel &
Towers.
“We are pleased to have our Xoft System for the treatment of early-stage
breast cancer so prominently featured before an audience of more than
1,000 of the world’s top breast surgeons at this premiere medical
conference,” said Ken Ferry, President and CEO of iCAD. “The data
presented further confirm the benefits of this therapy, and we look
forward to new and continued opportunities to advance the treatment of
breast cancer and improve the lives of patients.”
IORT data and innovations will be discussed in the following poster and
educational session:
-
“Intra-Operative Radiation Therapy for Treatment of Early Stage
Breast Cancer: Short Term Results from a Single Institution Clinical
Trial Using Electronic Brachytherapy with a Disposable Balloon
Applicator”
The poster (#56) will be available for viewing as
of 9:30 a.m. CT on Friday, May 3
Chicago Room 8-10, Level IV, Row
J.
Barbara S. Schwartzberg, MD, Rose Medical Center, Denver,
Colo., will review the results of a 51-patient trial of the Xoft®
Axxent® Electronic Brachytherapy System®,
finding no recurrences of breast cancer at an average of 14 months
post-treatment from 6:00 p.m.-7:30 p.m. CT on Friday evening at the
poster location.
-
“Innovations and Advances in Breast Cancer Diagnosis and Treatment”
Friday,
May 3, 4:00 p.m.-5:30 p.m. CT
Sheraton Chicago 4–7, Level IV
The
IORT portion of the General Session discussion will be led by Darius
S. Francescatti, MD, JD, FACS, Assistant Professor, Rush Presbyterian
St. Luke’s Medical Center, Chicago, Ill.
“IORT is a significant advancement in the treatment of breast cancer,
offering women a less burdensome option to traditional radiation therapy
and mitigating the arduous road to recovery many of these patients
face,” said Dr. Schwartzberg. “The data presented today show positive
outcomes with no recurrence of cancer, further validating the efficacy
of IORT for women with early-stage breast cancer.”
About Xoft® Axxent®
Electronic Brachytherapy System®
The Xoft System is an isotope-free radiation treatment cleared by the
U.S. Food and Drug Administration and CE marked for use anywhere in the
body, including for the treatment of early-stage breast cancer,
endometrial cancer, cervical cancer and skin cancer. It utilizes a
proprietary miniaturized x-ray as the radiation source that delivers
precise treatment directly to cancerous areas while sparing healthy
tissue and organs. A post-market study is underway to assess the safety
and efficacy of Intraoperative Radiation Therapy with the Xoft System.
Xoft, Inc. is a wholly owned subsidiary of iCAD, Inc. For more
information about Xoft visit www.xoftinc.com.
About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow
solutions and radiation therapies for the early identification and
treatment of common cancers. iCAD offers a comprehensive range of
high-performance, upgradeable CAD solutions for mammography and advanced
image analysis and workflow solutions for Magnetic Resonance Imaging,
for breast and prostate cancers and Computed Tomography for colorectal
cancer. iCAD’s Xoft System, offers radiation treatment for early-stage
breast cancer that can be administered in the form of Intraoperative
Radiation Therapy or accelerated partial breast irradiation. The Xoft
System is also cleared for the treatment of non-melanoma skin cancer,
endometrial and cervical cancers. For more information, call
877-iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s ability to defend itself in litigation matters, the
risks relating to the Company’s acquisition of Xoft including, the
expected benefits of the acquisition may not be achieved in a timely
manner, or at all; the Xoft business operations may not be successfully
integrated with iCAD’s and iCAD may be unable to achieve the expected
synergies, business and strategic objectives following the transaction,
the risks of uncertainty of patent protection; the impact of supply and
manufacturing constraints or difficulties; product market acceptance;
possible technological obsolescence; increased competition; customer
concentration; and other risks detailed in the Company’s filings with
the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”,
“anticipate”, “likely”, and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any
updates to any information contained in this release. For additional
disclosure regarding these and other risks faced by iCAD, please see the
disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website
at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
